Dr. Nicholas DiBella
Claim this profileRocky Mountain Cancer Centers-Boulder
About Nicholas DiBella
Education:
- Earned a Medical degree (MD) from an unspecified institution.
Experience:
- Founded Rocky Mountain Cancer Centers (RMCC) in 1992 and served as its former president.
- Served as Chairman of the Board for the Colorado Cancer Research Program.
- Held the position of Chairman for the US Oncology Hematology Research Committee.
- Played a key role in establishing The US Oncology Network, connecting over 1,400 oncologists nationwide.
- Retired as Medical Director at Rocky Mountain Breast Specialists.
Area of expertise
Breast Cancer
Nicholas DiBella has run 19 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Nicholas DiBella has run 18 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Rocky Mountain Cancer Centers-Boulder
Rocky Mountain Cancer Centers-Aurora
Clinical Trials Nicholas DiBella is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction. Fluorouracil is in a class of medications called antimetabolites. It stops cells from making DNA and may kill tumor cells. Leucovorin in a class of medications called folic acid analogs. When used with fluorouracil it enhances the effects of this chemotherapy drug. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair, and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Some patients on this trial will receive nivolumab, in addition to mFOLFOX or mFOLFIRINOX chemotherapy. mFOLFIRINOX with or without nivolumab may be more effective than mFOLFOX with or without nivolumab by shrinking the tumor in patients with advanced, unresectable, or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma.
Recruiting
2 awards
Phase 3
2 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
More about Nicholas DiBella
Clinical Trial Related
7 years of experience running clinical trials · Led 103 trials as a Principal Investigator · 17 Active Clinical Trials
Treatments Nicholas DiBella has experience with
- Nivolumab
- Pembrolizumab
- Cisplatin
- Atezolizumab
- Intensity-Modulated Radiation Therapy
- Fluorouracil
Breakdown of trials Nicholas DiBella has run
Breast Cancer
Lung Cancer
Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicholas DiBella specialize in?
Nicholas DiBella focuses on Breast Cancer and Lung Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Nicholas DiBella currently recruiting for clinical trials?
Yes, Nicholas DiBella is currently recruiting for 17 clinical trials in Boulder Colorado. If you're interested in participating, you should apply.
Are there any treatments that Nicholas DiBella has studied deeply?
Yes, Nicholas DiBella has studied treatments such as Nivolumab, Pembrolizumab, Cisplatin.
What is the best way to schedule an appointment with Nicholas DiBella?
Apply for one of the trials that Nicholas DiBella is conducting.
What is the office address of Nicholas DiBella?
The office of Nicholas DiBella is located at: Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado 80304 United States. This is the address for their practice at the Rocky Mountain Cancer Centers-Boulder.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.